FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 339:417-423 August 13, 1998 Number 7 Next

Abstract PDF Editorial by Kowdley, K. V. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Deferiprone is an orally active iron-chelation agent that is being evaluated as a treatment for iron overload in thalassemia major. Studies in an animal model showed that prolonged treatment is associated with a decline in the effectiveness of deferiprone and exacerbation of hepatic fibrosis.

Methods Hepatic iron stores were determined yearly by chemical analysis of liver-biopsy specimens, magnetic susceptometry, or both. Three hepatopathologists who were unaware of the patients' clinical status, the time at which the specimens were obtained, and the iron content of the specimens examined 72 biopsy specimens from 19 patients treated with deferiprone for more than one year. For comparison, 48 liver-biopsy specimens obtained from 20 patients treated with parenteral deferoxamine for more than one year were similarly reviewed.

Results Of the 19 patients treated with deferiprone, 18 had received the drug continuously for a mean (±SE) of 4.6±0.3 years. At the final analysis, 7 of the 18 had hepatic iron concentrations of at least 80 µmol per gram of liver, wet weight (the value above which there is an increased risk of cardiac disease and early death in patients with thalassemia major). Of 19 patients in whom multiple biopsies were performed over a period of more than one year, 14 could be evaluated for progression of hepatic fibrosis; of the 20 deferoxamine-treated patients, 12 could be evaluated for progression. Five deferiprone-treated patients had progression of fibrosis, as compared with none of those given deferoxamine (P=0.04). By the life-table method, we estimated that the median time to progression of fibrosis was 3.2 years in deferiprone-treated patients. After adjustment for the initial hepatic iron concentration, the estimated odds of progression of fibrosis increased by a factor of 5.8 (95 percent confidence interval, 1.1 to 29.6) with each additional year of deferiprone treatment.

Conclusions Deferiprone does not adequately control body iron burden in patients with thalassemia and may worsen hepatic fibrosis.

To determine whether the effects of deferiprone are sustained during long-term therapy, we measured hepatic iron during continued treatment of patients in whom body iron had been measured during short-term therapy.¹² To assess whether long-term therapy was associated with progression of hepatic fibrosis, a panel of hepatopathologists evaluated the liver-biopsy specimens obtained during this trial.

Methods

Patients

Of 21 previously studied patients who received deferiprone for a mean (±SE) of 3.1±0.3 years,¹² 19 continued to receive deferiprone at a dose of 75 mg per kilogram of body weight per day, while undergoing repeated biopsies for hepatic iron measurements. Long-term effectiveness could be evaluated in 18 patients, who had received the drug continuously for 4.6±0.3 years; 1 patient had stopped taking deferiprone shortly after the previous analysis, but the results of biopsies up to the discontinuation of therapy are included in the histologic analysis. Beginning in year 3 of the seven-year study, hepatic iron was measured by magnetic susceptometry in vivo.¹⁴ Because this technique does not provide histologic information, the follow-up period for effectiveness (range, 2 to 7 years) was longer than that for histologic analysis (range, 2 to 6 years).

Patients received regular transfusions. The objective of transfusion was to maintain the hemoglobin concentration above 9.5 g per deciliter. From November 1989 to November 1993, deferiprone was synthesized at the University of Toronto and encapsulated by NovaPharm Pharmaceuticals (Toronto). After November 1993, Apotex (Weston, Ont., Canada) supplied deferiprone tablets. The equivalence of the two formulations was not evaluated.

Body iron was evaluated in tissue obtained at biopsy, as described previously, and by magnetic susceptometry (Biomagnetic Technologies, San Diego, Calif.).^14,15 The magnetic measurements have been validated previously.¹⁴ We converted the concentration of iron in dried samples to a wet weight, assuming a liver water content of 70 percent; chemical and magnetic values were used interchangeably.¹²

In the original trial design, each biopsy specimen, obtained primarily to monitor therapeutic effectiveness, was histologically reviewed, but serial biopsy specimens were not prospectively compared. Concern about hepatotoxicity^13,16 prompted a retrospective review of these results and of those from a comparison group of 20 deferoxamine-treated patients. The comparison group included all patients eight years of age or older for whom the results of two or more biopsies performed one year apart during continuous deferoxamine treatment were available.

Efficacy Monitoring

A hepatic iron concentration of less than 80 µmol per gram of liver, wet weight, was considered to indicate effective iron-chelation therapy, and a concentration of 80 µmol or more per gram of liver, wet weight, was considered to indicate ineffective therapy.¹² These criteria, derived from a long-term trial in deferoxamine-treated patients,¹⁷ were used to evaluate the short-term effectiveness of deferiprone in our previous study¹² and were applied in an identical manner in the present long-term study. Similarly, a serum ferritin concentration of less than 2500 µg per liter was considered to indicate effective iron-chelation therapy, and higher values ineffective therapy.^12,18

Histologic Evaluation

An independent initial review of the biopsy specimens was carried out by the two study investigators who are hepatopathologists and a consultant. Before this review, the 72 biopsy slides were randomly arranged and each slide was assigned a unique number. Each pathologist graded the findings according to the system summarized in Table 1.¹⁹ Each was unaware of the patients' clinical status, the date each sample was obtained, and the hepatic iron content of each biopsy specimen. After the completion of the initial review, the two study investigators conducted a consensus review, in which all biopsy specimens were examined jointly, after standards regarding sample adequacy and definitions of progression and regression of fibrosis had been agreed on. The results of this evaluation were subsequently reviewed with the consultant, and a final decision was made with regard to the adequacy and stage of each biopsy specimen.

View this table: [in this window] [in a new window]   Table 1. System of Evaluating Hepatic-Biopsy Specimens for Architectural Changes, Fibrosis, and Cirrhosis.

 
Clinically significant progression of fibrosis was considered to have occurred if there was a change in the histologic score from 0 (no fibrosis) to 1 or greater, from 1 or 2 to 3 or greater, or from 3 or 4 to 5 or 6. Changes in the score from 1 to 2 or from 3 to 4 were not considered clinically significant. Similarly, a change in the score from 5 (incomplete cirrhosis) to 6 (probable or definite cirrhosis) was not considered clinically significant; hence, patients whose initial biopsy specimen showed cirrhosis could not be evaluated for progression of fibrosis. A biopsy specimen was considered adequate if two or more portal tracts were present. This was considered the absolute minimum necessary for the assessment of fibrosis and cirrhosis, since the ability to identify these processes varies considerably depending on the size of the biopsy specimen.

Monitoring of Toxicity and Compliance

Other types of safety monitoring in this study have been described previously.¹² Sexually active patients were asked to use reliable methods of contraception. We assessed compliance by monitoring the frequency with which pill bottles were opened, using bottles with microprocessors in the caps.^12,20

Statistical Analysis

Data are presented as means ±SE. Medians and ranges are given for continuous variables, and proportions are given for dichotomous variables. Pretreatment variables were compared between treatment groups by the Mann–Whitney test for continuous variables and by the Fisher–Irwin exact test for dichotomous variables.²¹ The Wilcoxon signed-rank test was used to compare pretreatment and post-treatment values for continuous variables and to assess whether there was a change in compliance during the last two years of deferiprone therapy. The Kaplan–Meier product-limit method was used to estimate the probability that each patient would not have progression of fibrosis for a specified period. The log-rank test was used to compare differences in the length of time to the progression of fibrosis in the treatment groups.²² Because the only patients with progression of fibrosis were in the deferiprone group, it was not possible to estimate the risk or odds of progression to fibrosis on the basis of the type of chelating therapy, the dichotomous predictor variable. Thus, multivariate logistic-regression models were formed to examine the relation between the dependent variable, progression of hepatic fibrosis, and predictor variables, including the duration of deferiprone therapy, age at initial biopsy, sex, the presence of antibody to hepatitis C virus, initial hepatic iron concentration, and the amount of blood transfused.²³ Stepwise analysis and an analysis of all possible subgroups were performed to choose the most parsimonious model with statistically significant predictors. All tests were two-tailed; a P value of 0.05 was considered to indicate statistical significance. The BMDP (BMDP Statistical Software, Los Angeles) and S-PLUS (Statistical Sciences, version 3.3 for Windows, Seattle) statistical computer packages were used for computations.

The study was approved by the human subjects committee of the Hospital for Sick Children, Toronto, and the Health Protection Branch of Health Canada. Written informed consent was obtained from each patient or the patients' parents.

Results

Effectiveness of Deferiprone

Among the 18 patients in whom the effectiveness of deferiprone could be evaluated, the mean (±SE) hepatic iron concentration decreased from 88.7±12.1 to 65.5±7.9 µmol per gram of liver, wet weight (normal value, about 1.6), after a mean of 4.6±0.3 years of therapy (range, 2 to 7); this decrease of 23.2±10.9 µmol of iron per gram of liver, wet weight, was not significant (P=0.07). Initial and final hepatic iron concentrations are shown in Figure 1. In seven patients, hepatic iron concentrations at the end of treatment met or exceeded the threshold value of 80 µmol per gram of liver, wet weight, which is associated with an increased risk of cardiac disease and early death.¹⁷ The serum ferritin concentration decreased from 4455±841 µg per liter at the beginning of treatment to 2831±491 µg per liter at the end of treatment. Expressed logarithmically, this decrease was significant (P=0.03). In nine of the patients, the serum ferritin concentration exceeded 2500 µg per liter, the threshold used to distinguish effective from ineffective chelation therapy.^12,18

View larger version (6K): [in this window] [in a new window]   Figure 1. Initial and Final Hepatic Iron Concentrations in 18 Patients with Thalassemia Major Treated with Deferiprone. The dashed line indicates the value of 80 µmol of iron per gram of liver tissue, wet weight, above which there is an increased risk of cardiac disease and early death due to iron loading during long-term treatment with deferoxamine.17 Squares indicate concentrations determined by liver biopsy, and circles concentrations determined by magnetic susceptometry.

 
Data on compliance were available for all 18 patients for the last two full years of treatment. The median rate of compliance each year was 98 percent, with ranges of 90 to 100 percent for the penultimate year and 87 to 100 percent for the final year (P=0.70).

Histologic Analysis

Of the 72 biopsy specimens available from the patients treated with deferiprone, 17 (24 percent) were judged inadequate for evaluation. Histologic changes could not be evaluated in five patients: two did not have two adequate biopsy specimens that had been obtained at least one year apart, and three had cirrhosis at the initial evaluation. Thus, a total of 55 biopsy specimens from 14 patients were examined (Table 2).

View this table: [in this window] [in a new window]   Table 2. Characteristics of the 14 Deferiprone-Treated Patients and the 12 Deferoxamine-Treated Patients in Whom Progression of Hepatic Fibrosis Could Be Evaluated.

 
Five patients treated with deferiprone had evidence of progression of fibrosis. The estimated median time to progression was 3.2 years. Figure 2 shows the initial and final histologic stages, hepatic iron concentrations, and duration of therapy for these five patients. In four patients, hepatic iron concentrations stabilized during therapy; in the fifth, the iron concentration decreased substantially. Figure 3 shows representative photomicrographs of liver specimens from the initial and final biopsies in these patients. In one other patient, there was an improvement in the histologic stage over a period of 3.5 years.

View larger version (8K): [in this window] [in a new window]   Figure 2. Changes in Histologic Findings and Hepatic Iron Concentrations in the Five Deferiprone-Treated Patients with Progression of Hepatic Fibrosis. The worst possible fibrosis score is 6; the staging system is described in Table 1.

 

View larger version (133K): [in this window] [in a new window]   Figure 3. Changes in Histologic Findings in the Five Deferiprone-Treated Patients with Progression of Hepatic Fibrosis. The top panels show the initial biopsy specimens, and the bottom panels the last biopsy specimens that could be evaluated (Masson's trichrome, x100).

 
Table 3 shows that deferiprone-treated patients with progression of fibrosis were older than those without progression (P=0.03). There were no other significant differences (sex, prevalence of hepatitis C infection, initial hepatic iron concentration, or the duration of therapy or amount of blood transfused between the initial biopsy and the final biopsy) between the two groups.

View this table: [in this window] [in a new window]   Table 3. Characteristics of the Patients with Progression of Hepatic Fibrosis during Treatment with Deferiprone and Those without Progression.

 
Of the 48 biopsy specimens available from the 20 patients treated with deferoxamine, 8 (17 percent) were judged inadequate for evaluation. Histologic changes could not be evaluated in eight patients: six did not have two adequate biopsy specimens that had been obtained at least one year apart, and two had cirrhosis at the initial evaluation. Thus, a total of 31 biopsy specimens from 12 patients were examined (Table 2). None of the specimens showed evidence of progression of fibrosis. In one patient, there was an improvement in the histologic stage over a two-year period.

After adjustment for initial hepatic iron concentrations, multivariate logistic-regression analysis showed that the estimated odds of progression to fibrosis increased by a factor of 5.8 (95 percent confidence interval, 1.1 to 29.6) with each additional year of deferiprone treatment. The deferiprone-treated patients had a significantly higher mean initial hepatic iron concentration than the deferoxamine-treated patients (P=0.01) (Table 2), but no significant differences between the two groups were identified with respect to age at initial biopsy, sex, prevalence of hepatitis C infection, or the duration of therapy or amount of blood transfused between the initial biopsy and the final biopsy.

Other Adverse Effects

Deferiprone therapy was not associated with clinically significant hematologic changes, as evidenced by regular blood counts. No characteristic abnormalities in liver function were observed, although many patients had the small elevations in serum aminotransferase concentrations that are commonly found during iron overload. In no patient did heart disease requiring medication develop during the study.

Discussion

These results indicate that deferiprone is not an effective means of iron-chelation therapy in patients with thalassemia major and may be associated with worsening of hepatic fibrosis, even in patients whose hepatic iron concentrations have stabilized or decreased. After a mean of 4.6 years of deferiprone therapy, body iron burden was at concentrations associated with a greatly increased risk of cardiac disease and early death¹⁷ in 7 of 18 patients (39 percent). Other investigators have recently reported that hepatic iron exceeded this threshold in 58 percent of patients who were treated with deferiprone for one to four years.²⁴ In our patients, differences in objectively determined rates of compliance or the rate of iron loading could not account for the lack of effectiveness of deferiprone.

The results of our review of liver-biopsy specimens suggest that extended deferiprone therapy may be associated with a worsening of hepatic fibrosis. Fibrosis progressed in 5 of the 14 patients (36 percent) in whom it could be evaluated, despite the stabilization of or a marked reduction in hepatic iron concentrations in all 5 patients. The estimated median time to progression of fibrosis was 3.2 years, and after adjustment for initial hepatic iron concentrations, the estimated odds of progression of fibrosis increased by a factor of 5.8 (95 percent confidence interval, 1.1 to 29.6) with each additional year of deferiprone treatment.

The worsening of hepatic fibrosis in deferiprone-treated patients is in contrast to the arrest of fibrosis regularly observed with deferoxamine therapy. In a seminal study, long-term therapy with deferoxamine halted the progression of hepatic fibrosis in patients with thalassemia major.^25,26,27 In these patients, progression was arrested despite a regimen of deferoxamine (0.5 g per day intramuscularly, six days per week)²⁵ now considered suboptimal because it merely stabilizes, rather than reduces, hepatic iron concentrations. Moreover, fibrosis was halted despite a final mean hepatic iron concentration (139 µmol per gram of liver, wet weight)²⁵ that was more than twice that in our deferiprone-treated patients with progression of fibrosis (49.5 µmol per gram of liver, wet weight). Subsequent studies²⁸ and the results in our comparison group of deferoxamine-treated patients confirm that modern regimens of parenteral deferoxamine arrest fibrosis.

Our findings virtually recapitulate those in a gerbil model of iron overload in which administration of a closely related drug (1,2-diethyl-3-hydroxypyridin-4-one) was associated with initial loss of efficacy, worsening of hepatic fibrosis, and cardiac fibrosis.¹³ There has been concern that hydroxypyridinones may exacerbate iron-related tissue damage.^29,30,31 Deferiprone is a bidentate chelator, and three molecules are needed to occupy the six coordination sites of a single atom of iron. In contrast, one molecule of the hexadentate deferoxamine binds a single atom of iron; the chelate (ferrioxamine) is virtually inert biologically. At low concentrations of deferiprone relative to the concentrations of available iron, partially bound forms of iron (bound to only one or two molecules of deferiprone) appear in which the unoccupied coordination sites remain reactive and able to catalyze the formation of hydroxyl radical or other reactive oxygen species.³² There is increasing evidence to suggest that these reactive oxygen species are involved in the pathogenesis of hepatic fibrosis. Recently, the potential cellular toxicity of deferiprone has been shown in erythrocytes³³ and cultured myocytes.³⁴

The limitations of our histopathological analysis should be emphasized: our analysis was retrospective, the number of patients studied was small, and the patients treated with deferoxamine do not constitute a true control population. Furthermore, histologic assessment was based on relatively few biopsy specimens, although this was true in both the deferiprone group and the deferoxamine group. Because this study was observational rather than randomized and the effect of hepatic fibrosis was not confirmed by challenge after discontinuation of the drug, the relation between deferiprone and fibrosis cannot be considered definite or proved. Nonetheless, we could identify no other causes of the accelerated fibrosis.

The patients with progression of fibrosis did not differ significantly from those without progression with respect to sex, prevalence of hepatitis C infection, initial hepatic iron concentrations, duration of therapy, or the rate of iron accumulation. The consensus of the pathologists was that there was no difference between groups in the type of inflammatory changes. Nonetheless, we cannot rule out the possibility of an interaction between deferiprone and hepatitis C infection. The patients with progression of fibrosis were older than those without progression, and the likelihood of progression of fibrosis was greater in patients with lower hepatic iron concentrations. Because we are unable to identify definite risk factors for accelerated fibrosis, we have discontinued deferiprone therapy in all patients, including those who are unable or unwilling to use deferoxamine in standard regimens.

Despite their limitations, the results of our analysis, together with theoretical considerations and findings in animal studies, indicate that deferiprone may worsen hepatic fibrosis. Before it can be considered for clinical use, even in patients who are unwilling or unable to use deferoxamine in standard regimens, prospective clinical trials are mandatory to evaluate the possibility of irreversible hepatic damage.

Supported in part by research grants from the Medical Research Council of Canada, the Ontario Heart and Stroke Foundation, the Ontario Thalassemia Foundation, the Cooley's Anemia Foundation, Apotex, and the National Institutes of Health (DK49108, HL58203, and HL61219). Dr. Olivieri is supported in part by a Scientist Award from the Medical Research Council of Canada.

We are indebted to Professor Peter Scheuer, London, for his independent analysis of the liver-biopsy slides; to David Nathan, David Weatherall, Michael Baker, Antonio Cao, Helen Chan, John Dick, Peter Durie, Brenda Gallie, Marc Giacomelli, John Harris, David Kern, F.A. Olivieri, Robert Phillips, Eliot Phillipson, Sergio Piomelli, Alvin Zipursky, and Stanley Zlotkin for ongoing encouragement, advice, and support; and to Naomi Klein, Maria Muraca, Allyson Muroff, and Helen Schinkel for assistance in data management.

References

1. Cooley's Anemia Progress Review Committee. Cooley's anemia: progress in biology and medicine. Bethesda, Md.: Division of Blood Diseases and Resources, 1995. 
2. Fosburg MT, Nathan DG. Treatment of Cooley's anemia. Blood 1990;76:435-444. [Free Full Text]
3. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-761. [Erratum, Blood 1997;89:2621.] [Free Full Text]
4. Bergeron RJ, Brittenham GM, eds. Development of iron chelators for clinical use. Boca Raton, Fla.: CRC Press, 1994.
5. Kontoghiorghes GJ, Aldouri MA, Sheppard LN, Hoffbrand AV. 1,2-dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet 1987;1:1294-1295. [Medline]
6. Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, et al. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies. Br J Haematol 1990;76:295-300. [Medline]
7. al-Refaie FN, Wonke B, Hoffbrand AV, Wickens DG, Nortey P, Kontoghiorghes GJ. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood 1992;80:593-599. [Free Full Text]
8. al-Refaie FN, Hershko C, Hoffbrand AV, et al. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br J Haematol 1995;91:224-229. [Medline]
9. Olivieri NF, Koren G, Hermann C, et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 1990;336:1275-1279. [CrossRef][Medline]
10. Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy AR, et al. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. Br J Haematol 1990;76:550-553. [Medline]
11. Agarwal MB, Gupte SS, Viswanathan C, et al. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol 1992;82:460-466. [Medline]
12. Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995;332:918-922. [Free Full Text]
13. Carthew P, Smith AG, Hider RC, Dorman B, Edwards RE, Francis JE. Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypyridinone iron chelator CP94. Biometals 1994;7:267-271. [Medline]
14. Brittenham GM, Farrell DE, Harris JW, et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982;307:1671-1675. [Abstract]
15. Overmoyer BA, McLaren CE, Brittenham GM. Uniformity of liver density and nonheme (storage) iron distribution. Arch Pathol Lab Med 1987;111:549-554. [Medline]
16. Wong A, Alder V, Robertson D, et al. Liver iron depletion and toxicity of the iron chelator deferiprone (L1, CP20) in the guinea pig. Biometals 1997;10:247-256. [CrossRef][Medline]
17. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-573. [Free Full Text]
18. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous -thalassemia. N Engl J Med 1994;331:574-578. [Free Full Text]
19. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699. [CrossRef][Medline]
20. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-3277. [Erratum, JAMA 1989;262:1472.] [Free Full Text]
21. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley, 1981.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
23. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39. [Medline]
24. Hoffbrand AV, Al-Refaie F, Davis B, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998;91:295-300. [Free Full Text]
25. Barry M, Flynn DM, Letsky EA, Risdon RA. Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress. BMJ 1974;2:16-20.
26. Risdon RA, Flynn DM, Barry M. The relation between liver iron concentration and liver damage in transfusional iron overload in thalassaemia and the effect of chelation therapy. Gut 1973;14:421-421. [Medline]
27. Risdon RA, Barry M, Flynn DM. Transfusional iron overload: the relationship between tissue iron concentration and hepatic fibrosis in thalassaemia. J Pathol 1975;116:83-95. [CrossRef][Medline]
28. Aldouri MA, Wonke B, Hoffbrand AV, et al. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine. J Clin Pathol 1987;40:1353-1359. [Free Full Text]
29. Halliwell B. Drug antioxidant effects: a basis for drug selection? Drugs 1991;42:569-605. [Medline]
30. Halliwell B. Iron, oxidative damage, and chelating agents. In: Bergeron RJ, Brittenham GM, eds. Development of iron chelators for clinical use. Boca Raton, Fla.: CRC Press, 1994:33-56.
31. Nathan DG. An orally active iron chelator. N Engl J Med 1995;332:953-954. [Erratum, N Engl J Med 1995;332:1315.] [Free Full Text]
32. Motekitis RJ, Martell AE. Stabilization of the iron (III) chelates of 1,2-dimethyl-3-hydroxypyrid-4-ones and related ligands. Inorg Chim Acta 1991;183:71-80.
33. Cragg L, Hebbel RP, Solovey A, Miller WJ, Enright H. The iron chelator L1 potentiates iron-mediated oxidative DNA damage. Blood 1996;88:Suppl 1:646a-646a.abstract 
34. Hershko C, Link G, Pinson A, Konijn AM. Deferiprone (L1) fails to mobilize iron and promotes iron cardiotoxicity at suboptimal L1/iron concentrations. Blood 1997;90:Suppl 1:11a-11a.abstract 

Abstract PDF Editorial by Kowdley, K. V. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Related Letters:

Iron Chelation with Oral Deferiprone in Patients with Thalassemia
Tricta F., Spino M., Callea F., Nathan D. G., Weatherall D. J., Stella M., Pinzello G., Maggio A., Wonke B., Telfer P., Hoffbrand A.V., Grady R. W., Giardina P. J., Cohen A. R., Martin M. B., Brittenham G. M., Fleming K. A., Templeton D. M., Olivieri N. F., Kowdley K. V., Kaplan M. M.
Extract | Full Text  
N Engl J Med 1998; 339:1710-1714, Dec 3, 1998. Correspondence

This article has been cited by other articles:

• Sade, R. M. (2009). Dangerous liaisons? Industry relations with health professionals.. J Law Med Ethics 37: 398-400  
• Otogawa, K., Ogawa, T., Shiga, R., Nakatani, K., Ikeda, K., Nakajima, Y., Kawada, N. (2008). Attenuation of acute and chronic liver injury in rats by iron-deficient diet. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294: R311-R320 [Abstract] [Full Text]  
• Aydinok, Y., Ulger, Z., Nart, D., Terzi, A., Cetiner, N., Ellis, G., Zimmermann, A., Manz, C. (2007). A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. haematol 92: 1599-1606 [Abstract] [Full Text]  
• Armand, P., Kim, H. T., Cutler, C. S., Ho, V. T., Koreth, J., Alyea, E. P., Soiffer, R. J., Antin, J. H. (2007). Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109: 4586-4588 [Abstract] [Full Text]  
• Tanner, M.A., Galanello, R., Dessi, C., Smith, G.C., Westwood, M.A., Agus, A., Roughton, M., Assomull, R., Nair, S.V., Walker, J.M., Pennell, D.J. (2007). A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance. Circulation 115: 1876-1884 [Abstract] [Full Text]  
• Stumpf, J. L. (2007). Deferasirox. Am J Health Syst Pharm 64: 606-616 [Abstract] [Full Text]  
• Porcu, M., Landis, N., Salis, S., Corda, M., Orru, P., Serra, E., Usai, B., Matta, G., Galanello, R. (2007). Effects of combined deferiprone and desferrioxamine iron chelating therapy in {beta}-thalassemia major end-stage heart failure. Eur J Heart Fail 9: 320-322 [Abstract] [Full Text]  
• Walker, E. M. Jr., Epling, C. P., Parris, C., Cansino, S., Ghosh, P., Desai, D. H., Morrison, R. G., Wright, G. L., Wehner, P., Mangiarua, E. I., Walker, S. M., Blough, E. R. (2007). Acetaminophen Protects Against Iron-Induced Cardiac Damage in Gerbils. Annals of Clinical & Laboratory Science 37: 22-33 [Abstract] [Full Text]  
• Neufeld, E. J. (2006). Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 107: 3436-3441 [Abstract] [Full Text]  
• Cohen, A. R. (2006). New Advances in Iron Chelation Therapy. ASH Education Book 2006: 42-47 [Abstract] [Full Text]  
• Kalinowski, D. S., Richardson, D. R. (2005). The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer. Pharmacol. Rev. 57: 547-583 [Abstract] [Full Text]  
• Sterba, M, Simunek, T, Mazurova, Y, Adamcova, M, Popelova, O, Kaplanova, J, Ponka, P, Gersl, V (2005). Safety and tolerability of repeated administration of pyridoxal 2-chlorobenzoyl hydrazone in rabbits. Hum Exp Toxicol 24: 581-589 [Abstract]  
• Savulescu, J. (2004). Thalassaemia major: the murky story of deferiprone. BMJ 328: 358-359 [Full Text]  
• Viens, A M, Savulescu, J (2004). Introduction to The Olivieri symposium. J. Med. Ethics 30: 1-7 [Full Text]  
• Koch, T (2003). Absent virtues: the poacher becomes gamekeeper. J. Med. Ethics 29: 337-342 [Abstract] [Full Text]  
• Cohen, A. R., Galanello, R., Piga, A., De Sanctis, V., Tricta, F. (2003). Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 102: 1583-1587 [Abstract] [Full Text]  
• Hoffbrand, A. V., Cohen, A., Hershko, C. (2003). Role of deferiprone in chelation therapy for transfusional iron overload. Blood 102: 17-24 [Full Text]  
• Brittenham, G. M., Nathan, D. G., Olivieri, N. F., Porter, J. B., Pippard, M., Vichinsky, E. P., Weatherall, D. J., Wanless, I. R., Sweeney, G., Dhillon, A. P., Guido, M., Piga, A., Galanello, R., Schwartz, E., Cohen, A. (2003). Deferiprone and hepatic fibrosis. Blood 101: 5089-5091 [Full Text]  
• Constantinou, G., Melides, S., Modell, B., Spino, M., Tricta, F., Nathan, D. G., Weatherall, D. J. (2003). The Olivieri Case. NEJM 348: 860-863 [Full Text]  
• Beutler, E., Hoffbrand, A. V., Cook, J. D. (2003). Iron Deficiency and Overload. ASH Education Book 2003: 40-61 [Abstract] [Full Text]  
• Nathan, D. G., Weatherall, D. J. (2002). Academic Freedom in Clinical Research. NEJM 347: 1368-1371 [Full Text]  
• Wanless, I. R., Sweeney, G., Dhillon, A. P., Guido, M., Piga, A., Galanello, R., Gamberini, M. R., Schwartz, E., Cohen, A. R. (2002). Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 100: 1566-1569 [Abstract] [Full Text]  
• Olivieri, N. (2002). I beg to differ. CMAJ 167: 11-11 [Full Text]  
• Angelucci, E., Muretto, P., Nicolucci, A., Baronciani, D., Erer, B., Gaziev, J., Ripalti, M., Sodani, P., Tomassoni, S., Visani, G., Lucarelli, G. (2002). Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 100: 17-21 [Abstract] [Full Text]  
• Rosenstock, L., Lee, L. J. (2002). Attacks on Science: The Risks to Evidence-Based Policy. AJPH 92: 14-18 [Abstract] [Full Text]  
• Hershko, C., Konijn, A. M., Nick, H. P., Breuer, W., Cabantchik, Z. I., Link, G. (2001). ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood 97: 1115-1122 [Abstract] [Full Text]  
• Kushner, J. P., Porter, J. P., Olivieri, N. F. (2001). Secondary Iron Overload. ASH Education Book 2001: 47-61 [Abstract] [Full Text]  
• Bodenheimer, T. (2000). Uneasy Alliance -- Clinical Investigators and the Pharmaceutical Industry. NEJM 342: 1539-1544 [Full Text]  
• Tsukamoto, H., Lin, M., Ohata, M., Giulivi, C., French, S. W., Brittenham, G. (1999). Iron primes hepatic macrophages for NF-kappa B activation in alcoholic liver injury. Am. J. Physiol. Gastrointest. Liver Physiol. 277: G1240-G1250 [Abstract] [Full Text]  
• Olivieri, N. F. (1999). The {beta}-Thalassemias. NEJM 341: 99-109 [Full Text]  
• Tsushima, R. G., Wickenden, A. D., Bouchard, R. A., Oudit, G. Y., Liu, P. P., Backx, P. H. (1999). Modulation of Iron Uptake in Heart by L-Type Ca2+ Channel Modifiers : Possible Implications in Iron Overload. Circ. Res. 84: 1302-1309 [Abstract] [Full Text]  
• Tricta, F., Spino, M., Callea, F., Nathan, D. G., Weatherall, D. J., Stella, M., Pinzello, G., Maggio, A., Wonke, B., Telfer, P., Hoffbrand, A.V., Grady, R. W., Giardina, P. J., Cohen, A. R., Martin, M. B., Brittenham, G. M., Fleming, K. A., Templeton, D. M., Olivieri, N. F., Kowdley, K. V., Kaplan, M. M. (1998). Iron Chelation with Oral Deferiprone in Patients with Thalassemia. NEJM 339: 1710-1714 [Full Text]  
• Kowdley, K. V., Kaplan, M. M. (1998). Iron-Chelation Therapy with Oral Deferiprone -- Toxicity or Lack of Efficacy?. NEJM 339: 468-469 [Full Text]